Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to $7.9 million.

  • Immucell's Non-Current Debt fell 1617.59% to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year decrease of 1617.59%. This contributed to the annual value of $9.0 million for FY2024, which is 1422.63% down from last year.
  • Immucell's Non-Current Debt amounted to $7.9 million in Q3 2025, which was down 1617.59% from $8.3 million recorded in Q2 2025.
  • Immucell's 5-year Non-Current Debt high stood at $10.9 million for Q3 2023, and its period low was $7.9 million during Q3 2025.
  • Over the past 5 years, Immucell's median Non-Current Debt value was $9.0 million (recorded in 2024), while the average stood at $9.2 million.
  • As far as peak fluctuations go, Immucell's Non-Current Debt soared by 1678.31% in 2022, and later crashed by 1617.59% in 2025.
  • Immucell's Non-Current Debt (Quarter) stood at $8.3 million in 2021, then grew by 10.38% to $9.2 million in 2022, then rose by 14.68% to $10.5 million in 2023, then dropped by 14.23% to $9.0 million in 2024, then fell by 12.63% to $7.9 million in 2025.
  • Its Non-Current Debt stands at $7.9 million for Q3 2025, versus $8.3 million for Q2 2025 and $8.7 million for Q1 2025.